Investor's Business Daily on MSN
Top 2% Travere Catapults To Profit-Taking Zone After Screaming Up Another Beat
Travere Therapeutics stock popped Friday — hitting a profit-taking zone — on another sales beat from its linchpin drug.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback